Caron Rigden

Medicine & Life Sciences

1. Aromatase Inhibitors 100%
2. Carboplatin 90%
3. Breast Neoplasms 74%
4. palbociclib 69%
5. thymidine kinase 1 66%
6. Circulating Tumor DNA 66%
7. Albumin-Bound Paclitaxel 64%
8. temsirolimus 60%
9. Pemetrexed 53%
10. Cetuximab 50%
11. Progression-Free Survival 50%
12. Letrozole 50%
13. 130-nm albumin-bound paclitaxel 50%
14. Triple Negative Breast Neoplasms 48%
15. Non-Randomized Controlled Trials 47%
16. Cholecalciferol 46%
17. Docetaxel 45%
18. Squamous Cell Carcinoma of Head and Neck 45%
19. Therapeutics 43%
20. Tamoxifen 42%
21. Arthralgia 42%
22. Rectal Neoplasms 41%
23. Head and Neck Neoplasms 40%
24. Hormones 37%
25. Non-Small Cell Lung Carcinoma 36%
26. Nanoparticles 35%
27. Mutation 35%
28. Vitamin D 33%
29. Appointments and Schedules 32%
30. Neutropenia 29%
31. Radiotherapy 27%
32. Randomized Controlled Trials 27%
33. Fluorouracil 26%
34. Drug Therapy 26%
35. Clinical Trials 26%
36. Tumor Burden 24%
37. TOR Serine-Threonine Kinases 22%
38. Neoplasms 22%
39. Serum 20%
40. Morbidity 19%
41. Whole Exome Sequencing 17%
42. Leucovorin 15%
43. Oxaliplatin 15%
44. Fulvestrant 14%
45. Anastrozole 14%
46. Folic Acid Antagonists 13%
47. Albumins 13%
48. Medical Futility 12%
49. Survival Rate 12%
50. Maximum Tolerated Dose 11%